Docetaxel in the treatment of advanced non-small-cell lung cancer

Expert Rev Anticancer Ther. 2008 Aug;8(8):1207-22. doi: 10.1586/14737140.8.8.1207.


Systemic chemotherapy provides improvement in both survival and quality of life for patients with advanced non-small-cell lung cancer (NSCLC). Docetaxel is the only agent currently approved for both first- and second-line treatment of advanced NSCLC. Multiple randomized clinical trials have established the efficacy of platinum-docetaxel regimens for the first-line treatment of advanced NSCLC. Carboplatin-based regimens and nonplatinum combinations with docetaxel also have proven efficacy in first-line therapy. Combinations of docetaxel with various novel targeted agents have produced encouraging data in Phase II trials. This review article summarizes recent studies of docetaxel as a single agent and in combination regimens with cytotoxic or targeted therapies in the management of patients with advanced NSCLC.

Publication types

  • Review

MeSH terms

  • Aged
  • Antineoplastic Agents, Phytogenic / pharmacokinetics
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Antineoplastic Agents, Phytogenic / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Clinical Trials as Topic
  • Docetaxel
  • Humans
  • Lung Neoplasms / drug therapy*
  • Taxoids / pharmacokinetics
  • Taxoids / pharmacology
  • Taxoids / therapeutic use*


  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Docetaxel